RIPK1 and liver disorder: On the other hand, our findings illustrate that a specific targeting of the pro-inflammatory function of NF-κB — a pathway that is activated in most HCC [25] — could be revitalized as a chemo-preventive strategy in chronic human liver disease, if these strategies are specific enough not to attenuate the anti-carcinogenic effects of NEMO or RIPK1.